The median OS for these patients was not reached (95% CI, 35.9 months to not reached) for period 2 in EGFR-positive NSQ cancer and not reached (95% CI, not reached) in ALK-positive NSQ cancer and 28.4 months (95% CI, 25.8 to 30.0 months) in EGFR-positive NSQ cancer and 49.5 months (95% CI, 35.1 months to not reached) in ALK-positive NSQ cancer for period 1. This evidence concerns the gene ALK and cancer.